GlaxoSmithKline (GSK) reported revenue growth of 19% to 7.4 billion pounds in 1Q17.
Expense guidance for 2017 For full-year 2017, Anthem (ANTM) has projected the medical cost trend for its local group business to fall in the range of 6.5%–7.0%. To learn more…
In 1Q17, Anthem (ANTM) witnessed an increase of around 645,000 members in its commercial business on a quarter-over-quarter (or QoQ) basis.
Based on the company’s performance in 1Q17, Anthem (ANTM) has increased its 2017 revenue guidance by around $1.5 billion.
In 1Q17, Anthem (ANTM) witnessed an increase of around 70,000 members in its government business on a quarter-over-quarter (or QoQ) basis.
In 1Q17, Anthem (ANTM) reported revenues of around $22.3 billion, which is a year-over-year (or YoY) decline of around 9.9%.
In 1Q17, Eli Lilly and Boehringer Ingelheim launched Synjardy XR tablets in the US for patients with type 2 diabetes.
Over the last year, Eli Lilly’s (LLY) forward PE has traded in the range of 18.9x–25.5x.
Cialis sales decreased over 7% to $533.6 million during 1Q17, compared to $576.7 million for 1Q16.
Eli Lilly & Co.’s (LLY) Animal Health company, Elanco, reported an increase of 2% in revenues to $769.4 million in 1Q17, compared to $754.6 million in 1Q16.
Eli Lilly & Co.’s (LLY) Human Pharmaceuticals segment includes the oncology franchise, which includes drugs like Alimta, Erbitux, Cyramza, and new entrant Portrazza.
Strattera, a drug for attention-deficit hyperactivity disorder, reported a 4% increase in revenues to $196.2 million in 1Q17, compared to $188.1 million in 1Q16.
Eli Lilly & Co.’s (LLY) new products include Cyramza, Basaglar, Jardiance, and Lartruvo.
Eli Lilly’s sales of Forteo increased ~9% to $347.5 million in 1Q17, compared to $318.6 million in 1Q16.
The growth for Eli Lilly’s Human Pharmaceuticals segment, which contributes ~85.3% to its total revenues, was driven by increased sales of products such as Trulicity, Humalog, and Cyramza.
Eli Lilly & Co. (LLY) released its 1Q17 earnings on April 25, 2017, reporting 7% growth in its top line for 1Q17 compared to 1Q16. LLY stock has risen ~4.2% in the last 12 months.
In 1Q17, Amgen’s (AMGN) Prolia continued to be a dominant player in the bone health segment. Indicated for postmenopausal osteoporosis, the drug managed to gain market share across all geographies in 1Q17.
In 1Q17, Amgen’s (AMGN) Enbrel witnessed a fall in unit demand, in line with the trend witnessed in 2016.
On March 3, 2017, Amgen (AMGN) presented interim data from its Phase 3 trial, ENDEAVOR. The data showed the superiority of a combination therapy of Kyprolis and dexamethasone over Velcade.
On March 3, 2017, Amgen announced positive results from its Phase 3 trial 482 study evaluating the efficacy of Xgeva in delaying skeletal-related events or bone complications in multiple myeloma patients.